COVID-19 Vaccine Safety in Children and Adolescents: First Pediatric Cases of Acute Tubulointerstitial Nephritis

Strategic Insights -

A recent study published in Human Vaccines & Immunotherapeutics has revealed two cases of adolescents who developed acute tubulointerstitial nephritis after receiving the second dose of the BNT162b2 COVID-19 mRNA vaccine. This is the first reported case of acute tubulointerstitial nephritis in pediatric patients linked to SARS-CoV-2 vaccination. The study highlights the importance of monitoring for potential side effects of COVID-19 vaccines in children and adolescents.

Key Takeaways:

  • The Food and Drug Administration (FDA) expanded the emergency use authorization for the BNT162b2 mRNA vaccine (Pfizer-BioNTech) for children aged 12-15 years on May 10, 2021.
  • The study found that despite various adverse events, the benefit of reducing the infection rate or frequency of severe COVID-19 outweighs the harm caused by COVID-19 vaccination.
  • The two adolescent cases of acute tubulointerstitial nephritis were reported after the second administration of the BNT162b2 vaccine, with no serious adverse events previously reported in 12-17-year-old recipients.
  • Researchers conclude that these cases are the first pediatric cases of acute tubulointerstitial nephritis temporarily linked to SARS-CoV-2 vaccination.

Statistics:

  • The study reports that two adolescent cases of acute tubulointerstitial nephritis were found after the second dose of the BNT162b2 vaccine.
  • The vaccine was previously approved for children aged 12-15 years on May 10, 2021.
  • The study highlights the importance of monitoring for potential side effects of COVID-19 vaccines in children and adolescents, with a focus on kidney health.

Sources:

  • Two adolescent cases of acute tubulointerstitial nephritis after second dose of COVID-19 mRNA vaccine. Human Vaccines & Immunotherapeutics, 2022:1-6.
  • Ki-Soo Kang, Dept. of Pediatrics, College of Medicine, Jeju National University, Jeju, South Korea.
  • Taylor & Francis Inc, 530 Walnut Street, Ste 850, Philadelphia, PA 19106, USA.